Empowered Funds LLC Purchases 18,487 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Empowered Funds LLC grew its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 5.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 377,906 shares of the medical instruments supplier’s stock after buying an additional 18,487 shares during the quarter. Empowered Funds LLC owned approximately 0.51% of OraSure Technologies worth $1,364,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Atom Investors LP bought a new stake in OraSure Technologies during the 3rd quarter worth approximately $49,000. Creative Planning acquired a new position in OraSure Technologies in the third quarter worth $54,000. Intech Investment Management LLC acquired a new position in OraSure Technologies in the third quarter worth $84,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of OraSure Technologies by 78.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 28,731 shares of the medical instruments supplier’s stock worth $123,000 after purchasing an additional 12,604 shares during the last quarter. Finally, Ballentine Partners LLC acquired a new stake in shares of OraSure Technologies in the third quarter valued at $159,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday.

OraSure Technologies Price Performance

OSUR stock opened at $3.93 on Monday. The company has a 50 day moving average price of $3.81 and a 200 day moving average price of $4.04. OraSure Technologies, Inc. has a fifty-two week low of $3.52 and a fifty-two week high of $8.04. The stock has a market capitalization of $293.14 million, a PE ratio of 26.20 and a beta of 0.05.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.